News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Batu Biologics Files Patent Covering New Use Of Approved Drug For Decreasing Cancer Immunotherapy Toxicity


5/12/2014 9:15:58 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Batu Biologics announced today filing of US patent #61/990231 covering the use of a commercially available drug, currently in use for other indications, for decreasing toxicity of immunotherapies such as interleukin-2. The patent is based on data demonstrating that the dosage of various cancer immune therapies is limited by toxicity of the therapy to the blood vessels of the patient, resulting in vascular leak syndrome, sepsis and death. Batu Biologics, through a series of in vitro and in vivo experiments, demonstrated that the dose of interleukin-2, a prototypic immunotherapy, can be increased by up to 100% when utilized together with the existing drug.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES